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Klavuzon is a naphthalen-1-yl substituted a,b-unsaturated d-lactone derivative, and is one of the anti-
proliferative members of this class of compounds. Asymmetric and racemic syntheses of novel a,b-
unsaturated d-lactone derivatives are important to investigate their potential for the treatment of cancer.
In this study, asymmetric and racemic syntheses of heteroatom-substituted klavuzon derivatives are
reported. The syntheses were completed by a well-known three-step procedure. Anti-proliferative activ-
ity of seven novel racemic klavuzon derivatives were reported against MCF-7, PC3, HCT116 p53+/+ and
HCT116 p53/ cancer cell lines. Topoisomerase I inhibitory properties of 5,6-dihydro-2H-pyran-2-one
derivatives were also studied.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Reactive electrophilic compounds, such as nitrogen mustards,
are still in use for chemotherapy of cancer patients [1,2]. Their
therapeutic effect is explained by the formation of an irreversible
covalent bond between mustards and DNA bases [3]. Similarly, a
compound that covalently binds to the active site of proteins
may inhibit the enzymatic activity of that protein irreversibly.
For example, it was reported that vicinal cysteine 504 and 505 resi-
dues are crucial for the catalytic mechanism of human topoiso-
merase I (Topo I) enzyme, a well-known target for anti-cancer
drugs [4], and thiol reactive electrophilic compounds may inhibit
the human Topo I activity [5,6].
Similarly, it is believed that a,b-unsaturated d-lactone deriva-
tives can covalently bind to the nucleophilic sites of proteins
through a Michael addition reaction, and this is the reason for
the resulting biological activity [7]. In the literature, hundreds of
compounds-either synthesized in the laboratory or isolated from
the natural resources- that have a functional group for this
type of reaction have been reported. Styryl lactones bear an
a,b-unsaturated d-lactone pharmacophore in their structures and
goniothalamin (GTN, 1) is a promising example of this class ofcompounds because of its reported selective anti-proliferative
activity on cancer cells [8,9].
To date many syntheses and SAR studies have been carried out
for goniothalamin derivatives. The presence of an a,b-unsaturated
carbonyl group and a trans C@C double bond are essential for the
biological activity [10,11]. The (R)-isomer is more potent and trig-
gers apoptosis, while the (S)-isomer causes autophagy in the cell
[12]. In another work, it has been shown that racemic goniothala-
min induces TP53 transcription-dependent and -independent
apoptosis in hepatocellular carcinoma (HCC)-derived p53 (TP53)-
positive and -negative cells [13]. A heteroatom substitution, that
donates a pairs of electrons to the benzene ring (2–4), decreases
anti-proliferative activity of goniothalamin. In the same study,
compounds having LogP values between +4.4 and +4.7 were more
potent [14]. Recently, Barcelos et al. reported that a 2,4-dimethoxy
analog (5) was approximately twice as potent as goniothalamin
(Fig. 1) [15].
Compound 6, conformationally constrained analog of
(R)-goniothalamin, and klavuzon (7) are a,b-unsaturated
d-lactone derivatives that were first described by our group in
2008. Conformationally constrained analog (6) has similar
anti-proliferative activity compared to (R)-goniothalamin, while
klavuzon (7) is more anti-proliferative than goniothalamin.
Presence of a methyl substitution in the naphthalene-1-yl group
(8 and 9) further increases its potency (Fig. 1) [16,17].
In this study, asymmetric and racemic preparations of novel
derivatives of klavuzon (10–15) and goniothalamin (16) were
Fig. 1. Structures of heteroatom-substituted goniothalamin (2–5) and 6-bicycloaryl
substituted (R)-5,6-dihydro-2H-pyran-2-one (6, 9) derivatives.
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biological activity of klavuzon were also investigated.2. Results and discussions
2.1. Chemistry
The syntheses of novel 5,6-dihydro-2H-pyran-2-one derivatives
(10–16) were planned by a well-known three-step procedure.
Asymmetric or racemic allylation of aldehydes was followed by
acrylate aster formation and ring-closing metathesis.
Asymmetric allylation of the 4-dimethylamino-1-
naphthaldehyde (17) was performed by allyltrimethoxysilane in
the presence of R-Tol-BINAP.AgF complex at 20 C to produce
R-homoallylic alcohol 18 with 69% yield [18]. Chiral HPLC studies
with two separate chiral columns were performed to determine
the ee% of the product and it showed a single peak, which might
be the result of formation of a single enantiomer or poor resolution
of enantiomers in the columns. To check the enantiopurity of the
formed homoallylic alcohol (R)-18, it was reacted with acryloyl
chloride to form its acrylate ester. Transformation of the obtained
alcohol to acrylate ester (R-19) was monitored by TLC [16].
Although the formation of the product was observed in TLC, acry-
late ester was highly unstable in silica gel column chromatography.Fig. 2. Proposed klavuzon (10–15) and goniothalamin (16) derivatives.Purification of the crude product gave only elimination product 20
with 40% yield, so the enantiomeric purity of the formed alcohol
(R-18) could not be determined. It is likely that donation of the
lone pair of electrons from nitrogen atom to the naphthalene
was the driving force of this elimination (Scheme 1).
Similarly asymmetric allylation of 4-methyl-1-naphthaldehyde
at 20 C gave compound (R)-22 with 56% yield and 82% ee. When
the same reaction was performed at room temperature, the enan-
tiomeric excess of the reaction did not change (Scheme 2). All fur-
ther asymmetric allylation reactions were performed both at
20 C and room temperature to show the applicability of asym-
metric allylation of 1-napthaldehydes at room temperature. Asym-
metric allylation of 4-methoxy-1-naphthaldehyde furnished
compound (R)-24 with almost the same enantiomeric excess at
20 C and room temperature (91% and 90% respectively). How-
ever, the yields of the products were low compared to the yield
of racemic allylation by a TBAT-CuCl mixture [19] (Scheme 3).
Asymmetric allylation of 2-methoxy-1-napthaldehyde and of
4,7-dimethoxy-1-naphthaldehyde gave similar results. The yields
of the asymmetric allylation are low compared to racemic
allylation and the enantiomeric excess of the reactions were quite
similar at 20 C and room temperature (50% and 55%, respec-
tively, for compound (R)-27, and 87% and 84%, respectively, for
compound (R)-30). The low enantiomeric excess for compound
(R)-27 can be explained by the proximity of the methoxy
substituent to the reaction center (Scheme 3 and 4). Surprisingly,
it appears that there was no effect of temperature on the
enantiomeric excess of the reactions.
To show the asymmetric synthesis of heteroatom-substituted
klavuzon derivatives, two chiral homoallylic alcohols, (R)-24 and
(R)-27, were transformed to their acrylate esters and then
converted to the lactones by ring-closing metathesis using a first
generation Grubbs’ catalyst [20]. To minimize the possible elimina-
tion reaction, esters were used without purification to produce
a,b-unsaturated d-lactones (Scheme 3).
Finally, racemic syntheses of compounds 10–16 were com-
pleted (Scheme 5). Briefly, racemic allylation of aldehydes (17,Scheme 1. Attempts towards the asymmetric synthesis of 40-
dimethylaminoklavuzon.
Scheme 2. Asymmetric allylation of 4-methyl-1-naphthaldehyde at room
temperature.
Entry Conditions
% yield, (%ee)
(R)-24 (R)-25 (R)-12 (R)-27 (R)-28 (R)-13
1 R-Tol-BINAP, AgF, MeOH, RT, 72 h 29, (90) NI 27* 30, (50) NI 25*
2 R-Tol-BINAP, AgF, MeOH, -20 oC, 75 h 50, (91) - - 22, (55)
3 TBAT, CuCl, THF, RT, 7 h 88, (rac.) 87, (rac.)
RT: Room Temperature; NI: Not Isolated;* yield for two steps; ee% calculated from chiral HPLC
Scheme 3. Asymmetric and racemic preparations of 40-methoxyklavuzon (12) and 40-methoxyklavuzon (13).
Entry Conditions
% yield, (%ee)
(R)-30
1 R-Tol-BINAP, AgF, MeOH, RT, 90 h 13, (84)
2 R-Tol-BINAP, AgF, MeOH, -20 oC, 73 h 9, (87)
3 TBAT, CuCl, THF, RT, 5 h 11, (rac.)
Scheme 4. Asymmetric allylation of 4,7-dimethoxy-1-naphttaldehyde (29) at
20 C and room temperature.
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allyltrimethoxysilane in the presence of TBAT-CuCl mixture. Yields
of the reactions were generally high (86–98%), except for
4-dimethylamino1-naphthaldehyde and 4,7-dimethoxy-1-
naphthaldehyde (54% and 11%, respectively).Scheme 5. Racemic preparations of klavuzon (10–15) and conNext, the formed homoallylic alcohols (18, 24, 27, 30, and
34–36) were subjected to acrylate ester formation with acryloyl
chloride. Yields of the esterification reactions were between 73%
and 97%, except for compound 18, which was used without
purification because of its decomposition in the silica gel column.
At the last step of synthesis, ring-closing metathesis reactions of
esters (19, 25, 28, and 37–40) were completed with 72–85% yields.
Similarly, the crude product of compound 19 was treated with
first-generation Grubbs’ catalyst to produce lactone 11 with 45%
yield (for the last two steps, Scheme 5).2.2. Biological activity
2.2.1. In vitro anti-proliferative activities of compounds
Anti-proliferative properties of the synthesized compounds 10–
16were studied by the MTT assay in four different cancer cell lines
(Table 1). Colon cancer cells (HCT116 p53+/+ and HCT116 p53/)
were more sensitive to the anti-proliferative activity of all tested
compounds. A similar result was also reported for racemic gonio-
thalamin treated p53-positive and -negative hepatocellular carci-
noma (HCC) cells [13]. It seems that cytotoxic behavior of tested
klavuzon derivatives exhibit similarity with that of racemic gonio-
thalamin and cytotoxic activity of both compounds is independent
with p53 protein expression. The anti-proliferative effect of com-formationally constrained goniothalamin (16) derivatives.
Table 1
In vitro anti-proliferative activities of compounds 10–16 on cancer cell lines in lM.
Compound MCF-7 PC3 HCT116
p53+/+ p53 /
(R)-1 19.00 4.00 nt nt
8 0.44 0.05 nt nt
10 22.42 1.68 0.03 0.01
11 nt nt 0.12 0.62
12 2.66 1.97 0.10 0.26
13 2.40 1.10 1.36 0.69
14 8.56 0.50 0.35 0.73
15 9.12 3.41 0.25 1.66
16 27.01 20.98 5.06 6.40
nt: not tested, Concentrations, that are needed to inhibit 50% of the cell growth,
were determined from nonlinear regression analysis of three separate experiments
performed in triplicate by using the GraphPad Prism software (R2 > 0.9).
Fig. 3. Topoisomerase I catalyzed relaxation of supercoiled DNA in the presence of
compounds (R)-GTN, 6, 7, 8 and 9. Lane 1, pUC19 (Supercoiled DNA, pHOT1 0,25 mg/
mL); lane 2, pUC19 + Topo I (1U) + DMSO; lanes 3–4, pUC19 + Topo I + 3 and 50 lM
CPT; lanes 5–6, pUC19 + Topo I + 10 and 1 mM (R)-goniothalamin; lanes 7–8, pUC19
+ Topo I + 10 and 1 mM compound 6; lanes 9–10, pUC19 + Topo I + 10 and 1 mM
compound 7; lanes 11–12, pUC19 + Topo I + 10 and 1 mM compound 8; lanes 13–14,
pUC19 + Topo I + 10 and 1 mM compound 9.
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reported by our group. Structurally, compound 10 is quite similar
to compound 8. Because both compounds have a hydrophobic car-
bon at position 4 of naphthalene-1-yl, we expected that compound
10 would possess similar potency compared to compound 8.
Unfortunately, it was found to be less active in MCF-7 and PC3 can-
cer cell lines, while it had the lowest IC50 values for HCT116 p53+/+
and HCT116 p53/ cancer cell lines.
Among the heteroatom-substituted klavuzon derivatives, com-
pounds 12 and 13 are analogous to compounds 8 and 9, respec-
tively. Comparison of their anti-proliferative activity implies that
a single methoxy substitution on naphthalene does not enhance
the activity as much as a single methyl group does for compounds
8 and 9. Dimethoxy substitution (14 and 15) does not make any
significant change in terms of biological activity, and compound
14 was found to be the most active molecule as it had IC50 values
at nanomolar concentrations in three cancer cell lines.
Besides, compound 16 was considered as the methoxy-
substituted conformationally constrained analog of goniothalamin.
In this case, a single methoxy substitution dramatically decreased
the potency of the compound compared with the IC50 values of
unsubstituted conformationally constrained goniothalamin analog
reported in the literature [16].Fig. 4. Topoisomerase I catalyzed relaxation of supercoiled DNA in the presence of compou
0,25 mg/mL); lane 3, pUC19 + Topo I (1U) + DMSO; lane 4, pUC19 + Topo I + 50 lM CPT; la
+ 10 and 50 mM compound 9; lanes 9–10, pUC19 + Topo I + 10 and 50 mM compound 13Up to date, there are many compounds which possess anti-
proliferative activity via interfering with Topo I action mechanism.
Topo I poisons, such as camptothecin (CPT) derivatives, reversibly
stabilize the Topo I-DNA complex [21] while Topo I catalytic inhi-
bitors, such as DNA intercalators [22,23] or Michael acceptors
[5,6,24,25], can only interacts with Topo I or DNA and prohibit
Topo I binding to DNA. Among these, Michael acceptors covalently
bind themselves to the nucleophilic thiol side chains of the target
proteins, and Montaudon and coworkers showed that among eight
cysteine residues in human topoisomerase I only Cys504 and
Cys505 residues are valuable targets for the inhibition of Topo I [6].
Since goniothalamin and klavuzon have a Michael acceptor in
their structure, derivatives of these compounds can also inhibit
Topo I activity by covalently binding to the Cys504 and Cys505
residues. Previously synthesis and anticancer property of confor-
mationally constrained (R)-goniothalamin derivatives have been
reported by our group [16]. As it can be seen in Fig. 3 (R)-
goniothalamin and its conformationally constrained analog (6)
inhibit Topo I at even 1 lM concentration. Similarly, (R)-klavuzon
(7), (R)-40-methylklavuzon (8) and (R)-20-methylklavuzon (9) also
inhibits Topo I mediated supercoiled DNA relaxation at 1 lM con-
centration. In general tested compounds showed similar Topo I
inhibition potency at 10 lM concentration compared to camp-
tothecin (CPT) at 50 lM concentration.
Newly synthesized heteroatom substituted racemic klavuzon
derivatives (10–15) and conformationally constrained goniothala-
min derivative (16) can also inhibit Topo I enzyme (Figs. 4 and
5). Replacement of methyl substituent with methoxide in klavuzon
structure at 20-position does not cause any significant effect in
Topo I inhibition potency (compounds 9 and 13 in Fig. 4). Interest-
ingly, 40-dimethylaminoklavuzon (11) and 20,30-dimethoxyklavu
zon (15) derivatives inhibits Topo I at higher concentration
(50 lM). Preincubation of Topo I enzyme with Michael acceptors
may also have influence in supercoiled DNA relaxation assay.
Topoisomerase I enzyme was preincubated only with
40methylklavuzon (8) for 0, 1, 5 and 10 min prior to the addition
of supercoiled DNA (Fig. 6). While there was not any significant
Topo I enzyme inhibition after 0 and 1 min of preincubation, 5
and 10 min of preincubation is enough for Topo I inhibition.
It seems quite difficult to correlate strong antiproliferative
activity in cancer cells with inhibition of Topo I relatively at higher
doses for klavuzon derivatives. But this may not be the case due to
two reasons. Firstly, all supercoiled DNA relaxation assays were
performed at pH of 8 as they were advised by the manufacturer.
Addition of thiols residues to Michael acceptors can be turned on
or off by depending on the pH of the reaction medium. Michael
addition reaction is irreversible and extremely slow at low pH
while it is reversible and faster at basic pH values [26]. Previously,
it was shown that Michael addition of thiols is a time dependent
equilibrium equation. After the reaction reach to equilibrium point,
concentrations of both starting material and adduct are almost
similar [26].
Secondly, amongst the different subcellular compartments only
mitochondria has a relatively basic medium (pH = 8) to support a
reversible Michael addition reaction. Some other intracellular com-
partments, such as nucleus, cytosol, endoplasmic reticulum andnds 12–14 and 9. Lane 1, 1 kB DNA Ladder; Lane 2, pUC19 (Supercoiled DNA, pHOT1
nes 5–6, pUC19 + Topo I + 10 and 50 mM compound 12; lanes 7–8, pUC19 + Topo I
; lanes 11–12, pUC19 + Topo I + 10 and 50 mM compound 14.
Fig. 5. Topoisomerase I catalyzed relaxation of supercoiled DNA in the presence of compounds 10, 11, 15, and 16. Lane 1, 1 kB DNA Ladder; Lane 2, pUC19 (Supercoiled DNA,
Phot1 0,25 mg/mL); lane 3, pUC19 + Topo I (1U) + DMSO; lane 4, pUC19 + Topo I + 50 lM CPT; lanes 5–6, pUC19 + Topo I + 10 and 50 mM compound 16; lanes 7–8, pUC19
+ Topo I + 10 and 50 mM compound 15; lanes 9–10, pUC19 + Topo I + 10 and 50 mM compound 10; lanes 11–12, pUC19 + Topo I + 10 and 50 mM compound 11.
Fig. 6. Time dependent Topoisomerase I catalyzed relaxation of supercoiled DNA in
the presence of compound 8: Lane1, pHOT1 (supercoiled DNA, 250 ng); lane 2,
relaxed DNA (100 ng); lane3, pHOT1 + Topo I + DMSO; lane4, pHOT1 + Topo I
+ 50 lM CPT; lanes 5–8, pHOT1 + Topo I pre-incubated with 100 lM compound 8
for 0, 1, 5 and 10 min.
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Remaining compartments, golgi network and lysosome, are quite
acidic (pH = 6.7–4.7) [27]. Also there are some evidence that cancer
cells may be more acidic [28]. It was reported that even at physio-
logical pH 7.4 Michael addition of glutathione to maleimide gave
almost 90% product formation [29]. Hence, outside the mitochon-
dria, all possible Michael addition reactions will be very slow and
irreversible. Possible reaction of Michael acceptors with Topo I
inside the nucleus would be slower but irreversible. This may
require lower doses of klavuzons inside the cell compared to that
of in vitro supercoiled DNA relaxation assay.
3. Conclusions
In this work, it has been shown that enantiomeric excess of the
asymmetric allylation of 1-naphthaldehyde derivatives catalyzed
by R-Tol-BINAP.AgF complex do not depend on temperature. Het-
eroatom substitution does not enhance the anti-proliferative activ-
ities of klavuzon derivatives, but 20,30-dimethoxy–substituted
klavuzon (14) was the most active compound and caused a 50%
inhibition of cell proliferation of three cancer cell lines at nanomo-
lar concentrations. Additionally it is found that both goniothalamin
and derivatives of klavuzon inhibit Topo I enzyme.
4. Experimental
4.1. Chemistry part
4.1.1. General procedures
Reagents were commercial grade and were used as supplied.
Dichloromethane was distilled over calcium hydride. Tetrahydro-
furan was dried by MBraun-SPS-Solvent Purification System. Reac-
tions were monitored by using Merck TLC plates (Silica gel 60 F
254). Chromatographic separations and isolations were performed
using Fluka 70–230 mesh silica gel. Solvents, required for SiO2 col-
umn chromatography, were commercial grade and were used as
supplied. Solvents, required for HPLC, were HPLC grade and were
used as supplied. 1H NMR and 13C NMR data were recorded on a
Varian 400-NMR (400 MHz) spectrometer. Chemical shifts for 1H
NMR and 13C NMR are reported in d (ppm). CDCl3 peaks were used
as reference in 1H NMR (7.26 ppm) and 13C NMR (77.16 ppm),respectively. MestreNova NMR Processing Software was used for
processing NMR spectra. Optical rotations were measured with
ADP 410 Digital Polarimeter (Bellingham + Stanley Ltd.). HPLC
studies were performed by employing Chiralcel OJ-H column
(0.46 cmU; 150 mm) on Agilent 1200 Series instrument.
4.1.2. General procedure for the synthesis of asymmetric homoallylic
alcohols (R-18, R-24, R-27, R-30 and R-22)
In a two necked round bottom flask 165 mg of R-Tol-BINAP
(0.24 mmol) and 52 mg of AgF (0.41 mmol) were placed and dis-
solved in 10 mL of anhydrous methanol. Solution was stirred about
20 min under nitrogen atmosphere at room temperature without
expose of light. Then solution mixture was cooled down to
20 C (room temperature for the reactions which was carried
out at room temperature) and 691 mg of 4-methyl-1-
naphthaldehyde (4.06 mmol) and 719 lL of allyltrimethoxysilane
(693 mg, 4.27 mmol) were added to reaction mixture respectively.
Final solution was allowed to stir 75 h at 20 C (room tempera-
ture for the reactions which was carried out at room temperature).
Then resulting mixture was filtered through celite-silica gel mix-
ture. Purification of crude product by column chromatography on
silica gel (1:10? 1:8 EtOAc/Hexane) furnished desired asymmet-
ric alcohol.
4.1.2.1. (R)-1-(4-(dimethylamino)naphthalen-1-yl)but-3-en-1-ol (R-
18). Purification of crude product by column chromatography on
silica gel (1:6, EtOAc:Hexane) furnished 167 mg of (R)-1-(4-(dime
thylamino)naphthalen-1-yl)but-3-en-1-ol as colorless oil, with
54% yield. Rf: 0,29 (1:6, EtOAc:Hexane); [a]D22 +182 (c 1.67, CH2Cl2);
Enantiomeric excess was found as 100% with Chiralcel OJ-H HPLC
column (Hexane:Isopropanol, 95:5, 1 mL/min, 320 nm, Rt = 7.70 -
min as single peak); 1H NMR (400 MHz, CDCl3) d 8.36–8.31 (m,
1H, naphthalene C5-H), 8.09–8.04 (m, 1H, naphthalene C8-H),
7.55 (d, J = 7.8 Hz, 1H, naphthalene C3-H), 7.54–7.49 (m, 2H, naph-
thalene C6-H and C7-H), 7.07 (d, J = 7.8 Hz, 1H, naphthalene C2-H),
6.01–5.88 (m, 1H,@CHA), 5.46–5.41 (m, 1H, benzylic H), 5.27–5.15
(m, 2H, @CH2), 2.90 (s, 6H, AN(CH3)2), 2.79–2.70 (m, 1H, ACHHA),
2.69–2.57 (m, 1H, ACHHA), 2.42 (s, 1H, AOH); 13C NMR (100 MHz,
CDCl3) d 150.60, 135.20, 133.97, 131.66, 129.01, 125.94, 124.99,
124.85, 123.48, 123.03, 118.01, 113.54, 70.05, 45.34, 42.78.
4.1.2.2. (R)-(+)-1-(4-methoxynaphthalen-1-yl)but-3-en-1-ol (R-
24). Purification of crude product by column chromatography on
silica gel (1:18, EtOAc:Hexane) furnished 113 mg of (R)-(+)-1-(4-
methoxynaphthalen-1-yl)but-3-en-1-ol as white solid with 50%
yield. Rf: 0.23 (1:6, EtOAc:Hexane); [a]D22 +181 (c 0.45, CH2Cl2);
Enantiomeric excess was found as 91% ee with Chiralcel OJ-H col-
umn (90:10 Hexane:Isopropanol, 1 mL/min; 280 nm, Rt1:
18.628 min as major peak, Rt2: 17.385 min as minor peak); 1H
NMR (400 MHz, CDCl3) d 8.38–8.32 (m, 1H, naphthalene C5-H),
8.06 (d, J = 8.7 Hz, 1H, naphthalene C8-H), 7.58–7.46 (m, 3H, naph-
thalene C2-H, C6-H and C7-H), 6.81 (d, J = 8.0 Hz, 1H, naphthalene
C3-H), 6.00–5.86 (m, 1H, @CHA), 5.44 (dd, J = 8.1, 4.3 Hz, 1H, ben-
zylic H), 5.26–5.14 (m, 2H, @CH2), 4.01 (s, 3H, AOCH3), 2.80–2.71
(m, 1H, ACHHA), 2.68–2.58 (m, 1H, ACHHA), 2.11 (s, 1H, AOH);
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126.72, 125.95, 125.04, 123.26, 122.98, 122.89, 118.25, 103.28,
70.15, 55.65, 42.88.
4.1.2.3. (R)-(+)-1-(2-methoxynaphthalen-1-yl)but-3-en-1-ol (R-27).
Purification of crude product by column chromatography on silica
gel (1:18, EtOAc:Hexane) furnished 50 mg of (R)-(+)-1-(2-methoxy
naphthalen-1-yl)but-3-en-1-ol as white solid, with 22% yield. Rf:
0.26 (1:6, EtOAc:Hexane); [a]D25 +64 (c 0.50, CH2Cl2); Enantiomeric
excess was found as 55% ee with Chiralcel OJ-H column (90:10
Hexane:Isopropanol, 1 mL/min; 280 nm, Rt1: 7.850 min as major
peak, Rt2: 11.596 min as minor peak); 1H NMR (400 MHz, CDCl3)
d 8.10 (d, J = 8.7 Hz, 1H, naphthalene C8-H), 7.82–7.77 (m, 2H,
naphthalene C4-H and C5-H), 7.52–7.46 (m, 1H, naphthalene
C6-H), 7.39–7.33 (m, 1H, naphthalene C7-H), 7.29 (d, J = 9.1 Hz,
1H, naphthalene C3-H), 5.97–5.85 (m, 1H, @CHA), 5.65–5.58 (m,
1H, benzylic H), 5.14 (d, J = 17.1 Hz, 1H, @CHH), 5.06 (d,
J = 10.2 Hz, 1H, @CHH), 4.01 (s, 3H, AOCH3), 3.91 (s, 1H, AOH),
2.91–2.81 (m, 1H, ACHHA), 2.70–2.61 (m, 1H, ACHHA); 13C NMR
(100 MHz, CDCl3) d 154.68, 135.63, 131.72, 129.51, 129.48,
128.75, 126.78, 124.11, 123.77, 123.16, 117.10, 113.37, 69.75,
56.49, 42.34.
4.1.2.4. (R)-(+)-1-(4,7-dimethoxynaphthalen-1-yl)but-3-en-1-ol (R-
30). Purification of crude product by column chromatography on
silica gel furnished (R)-(+)-1-(4,7-dimethoxynaphthalen-1-yl)but-
3-en-1-ol was collected as white solid with 9% yield. Rf: 0,08
(1:8, EtOAc:Hexane); [a]D25 +163 (c 0.16, CH2Cl2); Enantiomeric
excess was found as 87% ee with Chiralcel OJ-H column (90:10
Hexane:Isopropanol, 1 mL/min; 280 nm, Rt1: 10.189 min as major
peak, Rt2: 12.268 min as minor peak); 1H NMR (400 MHz, CDCl3)
d 8.23 (d, J = 9.2 Hz, 1H, naphthalene C5-H), 7.48 (d, J = 8.0 Hz,
1H, naphthalene C6-H), 7.35 (d, J = 2.1 Hz, 1H, naphthalene
C8-H), 7.17–7.11 (m, 1H, naphthalene C2-H), 6.66 (dd, J = 8.1,
3.0 Hz, 1H, naphthalene C3-H), 5.99–5.87 (m, 1H, @CHA), 5.33
(dd, J = 8.0, and 4.6 Hz, 1H, benzylic H), 5.21 (d, J = 17.2 Hz, 1H,
@CHH), 5.19–5.14 (m, 1H, @CHH), 3.97 (s, 3H, AOCH3), 3.92 (s,
3H, AOCH3), 2.79–2.70 (m, 1H, ACHHA), 2.69–2.59 (m, 1H,
ACHHA), 2.10 (s, 1H, AOH); 13C NMR (100 MHz, CDCl3) d 158.18,
155.34, 135.29, 132.90, 130.12, 124.51, 124.10, 120.99, 118.04,
116.74, 102.44, 101.36, 70.53, 55.53, 55.35, 42.37.
4.1.2.5. (R)-(+)-1-(4-methylnaphtalen-1-yl)but-3-en 1-ol (R-22).
Purification of crude product by column chromatography on silica
(1:10? 1:8 EtOAc/Hexane) furnished 479 mg of (R)-1-(4-
methylnaphtalen-1-yl)but-3-en 1-ol as light yellow oil with 56%
yield. Rf: 0.25 (1:6, EtOAc:Hexane); [a]D24 +223 (c 1.91, CH2Cl2);
Enantiomeric excess was found as 82% with Chiralcel OJ-H HPLC
column (Hexane:Isopropanol, 99:1, 1 mL/min, 280 nm,
Rt1 = 15.217 min as minor peak, Rt2 = 15.937 min as major peak);
1H NMR (400 MHz, CDCl3) d 8.14–8.09 (m, 1H, naphthalene
C8-H), 8.08–8.03 (m, 1H, naphthalene C5-H), 7.58–7.51 (m, 3H,
naphthalene C3-H, C6-H and C7-H), 7.34 (d, J = 7.3 Hz, 1H,
naphthalene C2-H), 6.01–5.88 (m, 1H, @CHA), 5.55–5.49 (m, 1H,
benzylic H), 5.26–5.16 (m, 2H, @CH2), 2.81–2.73 (m, 1H, ACHHA),
2.70 (s, 3H, ACH3), 2.67–2.57 (m, 1H, ACHHA), 2.12 (s, 1H, AOH);
13C NMR (100 MHz, CDCl3) d 137.59, 134.89, 133.47, 132.60,
130.22, 126.04, 125.34, 125.07, 124.70, 123.41, 122.46, 117.41,
69.76, 42.58, 19.38.
4.1.3. General procedure for the synthesis of racemic homoallylic
alcohols (34, 18, 24, 27, 35, 30 and 36)
A mixture of 20 mg of CuCl (0.20 mmol) and 111 mg of TBAT
(0.20 mmol) in 5 mL of THF was stirred for 1 h at room tempera-
ture. After cooling the mixture in an ice bath, 505 lL of
allyltrimethoxysilane (486 mg, 3.00 mmol) and 372 mg of6-methoxy-1-naphthaldehyde (2.00 mmol) were added and then
the cooling bath was removed. After starting material disappeared
on TLC, 2 M HCl aq. in MeOH (1:1) was added for desilylation.
Resulting mixture was extracted with ethyl acetate and collected
organic phase washed with brine (2  40 mL) dried with MgSO4.
After removing excess solvent under vacuum, crude product was
purified by column chromatography on silica gel (1:10? 1:6,
EtOAc/Hexane) to give desired alcohol.
4.1.3.1. 1-(1,2-Dihydroacenaphthylen-5-yl)but-3-en-1-ol (34). Purifi-
cation of crude product by column chromatography yielded
193 mg of 1-(1,2-dihydroacenaphthylen-5-yl)but-3-en-1-ol as
light yellow oil, with 86% yield. Rf: 0.32 (1:6, EtOAc:Hexane); 1H
NMR (400 MHz, CDCl3) d 7.79 (d, J = 8.4 Hz, 1H, naphthalene
C8-H), 7.57 (d, J = 7.1 Hz, 1H, naphthalene C2-H), 7.48 (dd, J = 8.3,
7.0 Hz, 1H, naphthalene C7-H), 7.33–7.27 (m, 2H, naphthalene
C3-H and C6-H), 6.02–5.80 (m, 1H, @CHA), 5.41 (brs, 1H, benzylic
H), 5.27–5.11 (m, 2H, @CH2), 3.45–3.34 (m, 4H, ACH2CH2A), 2.81–
2.57 (m, 2H,ACH2A), 2.19 (s, 1H,AOH); 13C NMR (100 MHz, CDCl3)
d 146.73, 145.91, 139.64, 135.47, 135.10, 135.08, 130.20, 128.92,
128.02, 127.92, 124.65, 119.33, 119.02, 118.98, 118.24, 70.55,
42.96, 30.66, 30.03.
4.1.3.2. 1-(4-(Dimethylamino)naphthalen-1-yl)but-3-en-1-ol (18).
Purification of crude product by column chromatography yielded
129 mg of 1-(4-(dimethylamino)naphthalen-1-yl)but-3-en-1-ol as
colorless oil, with 54% yield. Rf: 0.29 (1:6, EtOAc:Hexane); 1H
NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectral
data were consistent with previously reported values in 4.1.2.1.
4.1.3.3. 1-(4-Methoxynaphthalen-1-yl)but-3-en-1-ol (24). Purifica-
tion of crude product by column chromatography yielded 400 mg
of 1-(4-methoxynaphthalen-1-yl)but-3-en-1-ol as colorless oil,
with 88% yield. Rf: 0.23 (1:6, EtOAc:Hexane); 1H NMR (400 MHz,
CDCl3) and 13C NMR (100 MHz, CDCl3) spectral data were consis-
tent with previously reported values in 4.1.2.2.
4.1.3.4. 1-(2-Methoxynaphthalen-1-yl)but-3-en-1-ol (27). Purifica-
tion of crude product by column chromatography yielded 398 mg
of 1-(2-methoxynaphthalen-1-yl)but-3-en-1-ol as colorless oil,
with 87% yield. Rf: 0.26 (1:6, EtOAc:Hexane); 1H NMR (400 MHz,
CDCl3) and 13C NMR (100 MHz, CDCl3) spectral data were consis-
tent with previously reported values in 4.1.2.3.
4.1.3.5. 1-(2,3-Dimethoxynaphthalen-1-yl)but-3-en-1-ol (35). Purifi-
cation of crude product by column chromatography yielded
245 mg of 1-(2,3-dimethoxynaphthalen-1-yl)but-3-en-1-ol as
white solid, with 95% yield. Rf: 0.23 (1:6, EtOAc:Hexane); 1H
NMR (400 MHz, CDCl3) d 8.16 (d, J = 7.4 Hz, 1H, naphthalene
C8-H), 7.76–7.66 (m, 1H, naphthalene C5-H), 7.45–7.32 (m, 2H,
naphthalene C6-H and C7-H), 7.13 (s, 1H, naphthalene C4-H),
6.01–5.86 (m, 1H, @CHA), 5.67–5.56 (m, 1H, benzylic H),
5.22–5.07 (m, 2H, @CH2), 3.99 (s, 3H, AOCH3), 3.98 (s, 3H, AOCH3),
3.62 (brs, 1H, AOH), 2.92–2.80 (m, 1H, ACHHA), 2.72–2.61 (m, 1H,
ACHHA); 13C NMR (100 MHz, CDCl3) d 151.66, 147.21, 135.38,
131.69, 130.58, 127.43, 126.63, 125.32, 124.24, 124.06, 117.52,
107.50, 69.78, 61.74, 55.69, 43.13.
4.1.3.6. 1-(4,7-Dimethoxynaphthalen-1-yl)but-3-en-1-ol (30). Purifi-
cation of crude product by column chromatography yielded
57 mg of 1-(4,7-dimethoxynaphthalen-1-yl)but-3-en-1-ol as white
solid, with 11% yield. Rf: 0.09 (1:8, EtOAc:Hexane); 1H NMR
(400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectral data
were consistent with previously reported values in 4.1.2.4.
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tion of crude product by column chromatography yielded 449 mg
of 1-(6-methoxynaphthalen-2-yl)but-3-en-1-ol as white solid,
with 98% yield. Rf: 0.22 (1:6, EtOAc:Hexane); 1H NMR (400 MHz,
CDCl3) d 7.77–7.68 (m, 3H, naphthalene C1-H, C4-H and C8-H),
7.45 (dd, J = 8.6, 1.7 Hz, 1H, naphthalene C3-H), 7.18–7.11 (m, 2H,
naphthalene C5-H and C7-H), 5.90–5.77 (m, 1H, @CHA), 5.23–
5.11 (m, 2H, @CH2), 4.91–4.83 (m, 1H, benzylic H), 3.92 (s, 3H,
AOCH3), 2.65–2.55 (m, 2H, ACH2A), 2.11 (brs, 1H, AOH); 13C
NMR (100 MHz, CDCl3) d 157.85, 139.16, 134.64, 134.26, 129.57,
128.88, 127.21, 124.71, 124.59, 119.08, 118.53, 105.89, 73.60,
55.46, 43.89.
4.1.4. Synthesis of acrylate esters (37, 19, 20, 25, 28, 38–40)
A solution of 439 mg of 1-(6-methoxynaphthalen-2-yl)but-3-e
n-1-ol (1.92 mmol) in 12 mL of CH2Cl2 was cooled down to 0 C,
then 313 lL of acryloyl chloride (3.85 mmol) and 1.05 mL of tri-
ethylamine (7.53 mmol) were added sequentially. The mixture
was allowed to warm to room temperature and stirred until alco-
hol were consumed under nitrogen atmosphere. The final mixture
was filtered through celite, poured into water and extracted with
CH2Cl2. Combined organic phase concentrated under vacuum and
purification of crude product by column chromatography on silica
gel (EtOAc:Hexane, 1:10) gave the corresponding acrylate ester.
4.1.4.1. 1-(1,2-Dihydroacenaphthylen-5-yl)but-3-en-1-yl acrylate
(37). Purification of crude product by column chromatography
yielded 173 mg of 1-(1,2-dihydroacenaphthylen-5-yl)but-3-en-1-
yl acrylate as light yellow oil with 80% yield. Rf: 0.65 (1:6,
EtOAc:Hexane); 1H NMR (400 MHz, CDCl3) d 7.88 (d, J = 8.4 Hz,
1H, naphthalene C8-H), 7.54–7.47 (m, 2H, naphthalene C2-H and
C7-H), 7.31 (d, J = 6.9 Hz, 1H, naphthalene C3-H), 7.27 (d,
J = 7.7 Hz, 1H, naphthalene C6-H), 6.54 (t, J = 6.8 Hz, 1H, benzylic
H), 6.45 (d, J = 17.3 Hz, 1H, ACOCH@CHH), 6.24–6.14 (m, 1H,
ACOCH@CH2), 5.86–5.74 (m, 2H, ACH@ and ACOCH@CHH), 5.13
(d, J = 17.1 Hz, 1H, @CHH), 5.06 (d, J = 10.2 Hz, 1H, @CHH), 3.44–
3.33 (m, 4H, ACH2CH2A), 2.95–2.78 (m, 2H, ACH2A); 13C NMR
(100 MHz, CDCl3) d 165.57, 146.70, 146.60, 139.67, 133.78,
131.67, 130.92, 129.10, 128.77, 128.19, 126.06, 119.46, 119.29,
118.89, 118.01, 73.24, 40.29, 30.60, 30.10.
4.1.4.2. 1-(4-(Dimethylamino)naphthalen-1-yl)but-3-en-1-yl acrylate
(19). Purification was not performed. It was used without further
purification in next step. Rf: 0.52 (1:6, EtOAc:Hexane).
4.1.4.3. (E)-4-(buta-1,3-dien-1-yl)-N,N-dimethylnaphthalen-1-amine
(20). Purification of crude product by column chromatography on
silica gel furnished 22 mg of (E)-4-(buta-1,3-dien-1-yl)-N,N-
dimethylnaphthalen-1-amine as colorless oil with 40% yield as
elimination product. Rf: 0.75 (1:6, EtOAc:Hexane); 1H NMR
(400 MHz, CDCl3) d 8.32–8.25 (m, 1H, naphthalene C5-H), 8.18–
8.12 (m, 1H, naphthalene C8-H), 7.61 (d, J = 7.9 Hz, 1H, naph-
thalene C2-H), 7.55–7.49 (m, 2H, naphthalene C6-H and C7-H),
7.32 (d, J = 15.2 Hz, 1H, APhCH@), 7.07 (d, J = 7.9 Hz, 1H, naph-
thalene C3-H), 6.86–6.76 (m, 1H, @CHACH@), 6.72–6.62 (m, 1H,
@CHACH@), 5.37 (d, J = 16.7 Hz, 1H, @CHH), 5.21 (d, J = 9.9 Hz,
1H, @CHH), 2.91 (s, 6H, AN(CH3)2); 13C NMR (100 MHz, CDCl3) d
151.03, 137.80, 132.49, 131.09, 129.96, 129.31, 128.80, 126.05,
125.14, 124.83, 124.15, 123.67, 117.07, 113.96, 45.30.
4.1.4.4. 1-(4-Methoxynaphthalen-1-yl)but-3-en-1-yl acrylate
(25). Purification of crude product by column chromatography
yielded 348 mg of 1-(4-methoxynaphthalen-1-yl)but-3-en-1-yl
acrylate as white solid with 73% yield. Rf: 0.49 (1:8, EtOAc:Hex-
ane); 1H NMR (400 MHz, CDCl3) d 8.33 (d, J = 8.4 Hz, 1H, naph-
thalene C5-H), 8.13 (d, J = 8.4 Hz, 1H, naphthalene C8-H), 7.57(ddd, J = 8.5, 6.8, 1.5 Hz, 1H, naphthalene C6-H), 7.52–7.47 (m,
2H, naphthalene C3-H and C7-H), 6.80 (d, J = 8.0 Hz, 1H, naph-
thalene C2-H), 6.63–6.55 (m, 1H, benzylic H), 6.44 (dd, J = 17.3,
1.5 Hz, 1H, ACOCH@CHH), 6.19 (dd, J = 17.3, 10.4 Hz, 1H,
ACOCH@CH2), 5.87–5.71 (m, 2H, ACOCH@CHH and ACH@),
5.15–5.02 (m, 2H, @CH2), 4.00 (s, 3H, AOCH3), 2.88–2.81 (m, 2H,
ACH2A); 13C NMR (100 MHz, CDCl3) d 165.58, 155.64, 133.84,
131.63, 130.89, 128.83, 127.81, 126.97, 126.00, 125.16, 124.70,
123.20, 122.89, 117.97, 103.19, 72.89, 55.65, 40.34.
4.1.4.5. 1-(2-Methoxynaphthalen-1-yl)but-3-en-1-yl acrylate
(28). Purification of crude product by column chromatography
yielded 420 mg of 1-(2-methoxynaphthalen-1-yl)but-3-en-1-yl
acrylate as white solid, with 90% yield. Rf: 0.43 (1:8, EtOAc:Hex-
ane); 1H NMR (400 MHz, CDCl3) d 8.44 (d, J = 8.4 Hz, 1H, naph-
thalene C8-H), 7.82–7.76 (m, 2H, naphthalene C4-H and C5-H),
7.52–7.45 (m, 1H, naphthalene C6-H), 7.38–7.32 (m, 1H, naph-
thalene C7-H), 7.27 (d, J = 8.8 Hz, 1H, naphthalene C3-H), 6.97
(dd, J = 8.3, 6.8 Hz, 1H, benzylic H), 6.39 (dd, J = 17.3, 1.3 Hz, 1H,
ACOCH@CHH), 6.15 (dd, J = 17.3, 10.4 Hz, 1H, ACOCH@CH2),
5.87–5.74 (m, 2H, ACH@ and ACOCH@CHH), 5.08 (ddd, J = 17.1,
3.1, and 1.6 Hz, 1H, @CHH), 5.01 (ddt, J = 10.2, 1.9, and 1.1 Hz,
1H, @CHH), 3.99 (s, 3H, AOCH3), 3.15–3.04 (m, 1H, ACHHA),
2.88–2.77 (m, 1H, ACHHA); 13C NMR (100 MHz, CDCl3) d 165.59,
155.04, 134.19, 132.14, 130.59, 130.43, 129.93, 128.95, 128.92,
126.41, 124.87, 123.51, 120.77, 117.49, 114.00, 69.97, 57.30, 39.16.
4.1.4.6. 1-(2,3-Dimethoxynaphthalen-1-yl)but-3-en-1-yl acrylate
(38). Purification of crude product by column chromatography
yielded 270 mg of 1-(2,3-dimethoxynaphthalen-1-yl)but-3-en-1-
yl acrylate as white solid 97% yield. Rf: 0.41 (1:6, EtOAc:Hexane);
1H NMR (400 MHz, CDCl3) d 8.41–8.37 (m, 1H, naphthalene C8-
H), 7.74–7.69 (m, 1H, naphthalene C5-H), 7.41–7.34 (m, 2H, naph-
thalene C6-H and C7-H), 7.14 (s, 1H, naphthalene C4-H), 6.89 (dd,
J = 8.4, 6.8 Hz, 1H, benzylic H), 6.41 (d, J = 17.4 Hz, 1H,
ACOCH@CHH), 6.16 (dd, J = 17.4, 10.3 Hz, 1H, ACOCH@CH2),
5.87–5.75 (m, 2H, ACH@ and ACOCH@CHH), 5.12–5.00 (m, 2H,
@CH2), 4.03 (s, 3H, AOCH3), 3.98 (s, 3H, AOCH3), 3.15–3.05 (m,
1H, ACHHA), 2.87–2.77 (m, 1H, ACHHA); 13C NMR (100 MHz,
CDCl3) d 165.57, 151.72, 147.54, 133.93, 131.95, 130.85, 128.76,
127.62, 127.05, 126.64, 125.11, 125.08, 124.03, 117.84, 107.99,
70.62, 61.24, 55.69, 39.40.
4.1.4.7. 1-(4,7-Dimethoxynaphthalen-1-yl)but-3-en-1-yl acrylate
(39). Purification of crude product by column chromatography
yielded 56 mg of 1-(4,7-dimethoxynaphthalen-1-yl)but-3-en-1-yl
acrylate as white solid with 82% yield. Rf: 0.45 (1:6, EtOAc:Hex-
ane); 1H NMR (400 MHz, CDCl3) d 8.22 (d, J = 9.2 Hz, 1H, naph-
thalene C5-H), 7.47 (d, J = 8.1 Hz, 1H, naphthalene C2-H), 7.41 (d,
J = 2.5 Hz, 1H, naphthalene C8-H), 7.14 (dd, J = 9.2, 2.5 Hz, 1H,
naphthalene C6-H), 6.67 (d, J = 8.1 Hz, 1H, naphthalene C3-H),
6.57–6.51 (m, 1H, benzylic H), 6.44 (dd, J = 17.3, 1.5 Hz, 1H,
ACOCH@CHH), 6.17 (dd, J = 17.3, 10.4 Hz, 1H, ACOCH@CH2),
5.87–5.74 (m, 2H, ACH@ and ACOCH@CHH), 5.17–5.10 (m, 1H,
@CHH), 5.10–5.04 (m, 1H, @CHH), 3.98 (s, 3H, AOCH3), 3.94 (s,
3H, AOCH3), 2.91–2.82 (m, 2H, ACH2A); 13C NMR (100 MHz,
CDCl3) d 165.70, 158.49, 155.87, 133.93, 133.24, 130.97, 128.80,
126.35, 125.57, 124.56, 121.04, 118.00, 117.18, 102.43, 101.35,
72.82, 55.58, 55.42, 39.74.
4.1.4.8. 1-(6-Methoxynaphthalen-2-yl)but-3-en-1-yl acrylate
(40). Purification of crude product by column chromatography
yielded 455 mg of 1-(6-methoxynaphthalen-2-yl)but-3-en-1-yl
acrylate as colorless oil with 84% yield. Rf: 0.52 (1:6, EtOAc:Hex-
ane); 1H NMR (400 MHz, CDCl3) d 7.77–7.70 (m, 3H, naphthalene
C1-H, C4-H and C8-H), 7.46 (dd, J = 8.4, 1.7 Hz, 1H, naphthalene
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J = 2.4 Hz, 1H, naphthalene C5-H), 6.44 (dd, J = 17.3, 1.5 Hz, 1H,
ACOCH@CHH), 6.18 (dd, J = 17.3, 10.4 Hz, 1H, ACOCH@CH2),
6.07–6.00 (m, 1H, benzylic H), 5.83 (dd, J = 10.4, 1.5 Hz, 1H,
ACOCH@CHH), 5.81–5.68 (m, 1H, ACH@), 5.15–5.01 (m, 2H,
@CH2), 3.92 (s, 3H, AOCH3), 2.86–2.75 (m, 1H, ACHHA), 2.75–
2.65 (m, 1H, ACHHA); 13C NMR (100 MHz, CDCl3) d 165.55,
158.05, 135.16, 134.44, 133.42, 130.91, 129.68, 128.81, 128.71,
127.25, 125.84, 125.05, 119.18, 118.23, 105.84, 75.70, 55.45, 40.76.
4.1.5. Synthesis of 5,6-dihydro-2H-pyran-2-ones (Klavuzon
derivatives) (10–16)
To a solution of 434 mg of 1-(6-methoxynaphthalen-2-yl)but-3-
en-1-yl acrylate (1.54 mmol) in 154 mL of CH2Cl2 (0.01 M) was
heated to 45 C, and 130 mg of 1st Generation Grubbs’ catalyst
(0.16 mmol) in 16 mL of CH2Cl2 (0.01 M) was added to the solution.
The resulting mixture was heated at reflux until all starting mate-
rial consumed. At the end of the reaction, solution was cooled
down to room temperature and concentrated under vacuum.
Purification of crude product by column chromatography on silica
gel (EtOAc:Hexane, 1:5? 1:3) furnished the corresponding 5,6-
dihydro-2H-pyran-2-one.
4.1.5.1. 6-(1,2-Dihydroacenaphthylen-5-yl)-5,6-dihydro-2H-pyran-2-
one (10). Purification of crude product by column chromatography
yielded 109 mg of 6-(1,2-dihydroacenaphthylen-5-yl)-5,6-dihy
dro-2H-pyran-2-one as white solid with 80%. Rf: 0.33 (1:2,
EtOAc:Hexane); 1H NMR (400 MHz, CDCl3) d 7.71–7.65 (m, 1H,
naphthalene C8-H), 7.63–7.57 (m, 1H, naphthalene C2-H), 7.52–
7.45 (m, 1H, naphthalene C6-H), 7.36–7.27 (m, 2H, naphthalene
C3-H and C7-H), 7.07–6.99 (m, 1H, ACOCH@CHA), 6.24–6.17 (m,
1H, benzylic H), 6.12–6.04 (m, 1H, ACOCH@CHA), 3.41 (s, 4H,
ACH2CH2A), 2.93–2.67 (m, 2H, ACH2A); 13C NMR (100 MHz,
CDCl3) d 164.62, 147.36, 146.96, 145.46, 139.60, 129.86, 128.49,
126.04, 121.79, 119.70, 118.99, 118.98, 118.61, 77.33, 31.26,
30.65, 30.15; HRMS: C17H14O2Na found as [M+Na]+: 273.0891 (Cal-
culated for [M+Na]+: 273.0891).
4.1.5.2. 6-(4-(Dimethylamino)naphthalen-1-yl)-5,6-dihydro-2H-
pyran-2-one (11). Purification of crude product by column chro-
matography yielded 65 mg of 6-(4-(dimethylamino)naphthalen-1
-yl)-5,6-dihydro-2H-pyran-2-one as yellow jelly compound with
45% yield (overall yield from alcohol). Rf: 0.31 (1:2, EtOAc:Hex-
ane); 1H NMR (400 MHz, CDCl3) d 8.34–8.24 (m, 1H, naphthalene
C5-H), 7.99–7.89 (m, 1H, naphthalene C8-H), 7.62–7.45 (m, 3H,
naphthalene C3-H, C6-H and C7-H), 7.10–6.97 (m, 2H, naphthalene
C5-H and ACOCH@CHA), 6.24–6.08 (m, 2H, benzylic H and
ACOCH@CHA), 2.92–2.71 (m, 8H, AN(CH3)2 and ACH2A); 13C
NMR (100 MHz, CDCl3) d 164.66, 151.96, 145.49, 131.58, 129.11,
128.09, 126.57, 125.40, 125.16, 124.63, 123.14, 121.83, 113.39,
77.07, 45.31, 31.09; HRMS: C17H17NO2Na found as [M+Na]+:
290.1158 (Calculated for [M+Na]+: 290.1157).
4.1.5.3. 6-(4-Methoxynaphthalen-1-yl)-5,6-dihydro-2H-pyran-2-one
(12). Purification of crude product by column chromatography
yielded 272 mg of 6-(4-methoxynaphthalen-1-yl)-5,6-dihydro-
2H-pyran-2-one as white solid with 86% yield. Rf: 0.29 (1:2,
EtOAc:Hexane); 1H NMR (400 MHz, CDCl3) d 8.37–8.32 (m, 1H,
naphthalene C5-H), 7.94 (d, J = 8.4 Hz, 1H, naphthalene C8-H),
7.61–7.45 (m, 3H, naphthalene C2-H, C6-H and C7-H), 7.07–6.98
(m, 1H, ACOCH@CHA), 6.81 (d, J = 8.1 Hz, 1H, naphthalene C3-H),
6.22–6.17 (m, 1H, benzylic H), 6.10 (dd, J = 11.8, 4.2 Hz, 1H,
ACOCH@CHA), 4.01 (s, 3H, AOCH3), 2.90–2.79 (m, 1H, ACHHA),
2.78–2.69 (m, 1H, ACHHA); 13C NMR (100 MHz, CDCl3) d 164.64,
156.11, 145.50, 131.28, 127.22, 125.98, 125.86, 125.30, 124.87,
123.09, 122.59, 121.76, 103.14, 77.04, 55.71, 31.08; HRMS: C16H14-O3Na found as [M+Na]+: 277.0832 (Calculated for [M+Na]+:
277.0841).
4.1.5.4. 6-(2-Methoxynaphthalen-1-yl)-5,6-dihydro-2H-pyran-2-one
(13). Purification of crude product by column chromatography
yielded 290 mg of 6-(2-methoxynaphthalen-1-yl)-5,6-dihydro-
2H-pyran-2-one as white solid with 81% yield. Rf: 0.26 (1:2,
EtOAc:Hexane); 1H NMR (400 MHz, CDCl3) d 8.23 (d, J = 8.7 Hz,
1H, naphthalene C8-H), 7.85 (d, J = 9.1 Hz, 1H, naphthalene C4-
H), 7.80 (d, J = 8.1 Hz, 1H, naphthalene C5-H), 7.50–7.43 (m, 1H,
naphthalene C6-H), 7.38–7.32 (m, 1H, naphthalene C7-H), 7.26
(d, J = 9.1 Hz, 1H, naphthalene C3-H), 7.05 (ddd, J = 9.9, 6.2,
2.0 Hz, 1H, ACOCH@CHA), 6.54 (dd, J = 13.2, 4.3 Hz, 1H, benzylic
H), 6.20 (dd, J = 9.8, 2.8 Hz, 1H, ACOCH@CHA), 3.94 (s, 3H, AOCH3),
3.31–3.20 (m, 1H, ACHHA), 2.49–2.40 (m, 1H, ACHHA); 13C NMR
(100 MHz, CDCl3) d 164.94, 154.92, 146.32, 132.15, 131.35,
129.75, 129.01, 126.88, 124.47, 123.75, 121.48, 118.04, 113.18,
73.62, 56.85, 29.53; HRMS: C16H14O3Na found as [M+Na]+:
277.0845 (Calculated for [M+Na]+: 277.0841).
4.1.5.5. 6-(2,3-Dimethoxynaphthalen-1-yl)-5,6-dihydro-2H-pyran-2-
one (14). Purification of crude product by column chromatography
yielded 187 mg of 6-(2,3-dimethoxynaphthalen-1-yl)-5,6-dihydro-
2H-pyran-2-one as white solid with 82% yield. Rf: 0.28 (1:2, EtOAc:
Hexane); 1H NMR (400 MHz, CDCl3) d 8.15 (d, J = 8.2 Hz, 1H, naph-
thalene C8-H), 7.73 (d, J = 7.5 Hz, 1H, naphthalene C5-H), 7.43–7.33
(m, 2H, naphthalene C6-H and C7-H), 7.20 (s, 1H, naphthalene C4-
H), 7.06 (ddd, J = 9.8, 6.2, 1.9 Hz, 1H, ACOCH@CHA), 6.43 (dd,
J = 13.2, 4.3 Hz, 1H, ACOCH@CHA), 6.22 (dd, J = 9.9, 2.8 Hz, 1H,
benzylic H), 4.00 (s, 3H, AOCH3), 3.94 (s, 3H, AOCH3), 3.34–3.23
(m, 1H, ACHHA), 2.51–2.41 (m, 1H, ACHHA); 13C NMR
(100 MHz, CDCl3) d 164.61, 151.53, 147.94, 146.17, 131.90,
127.72, 126.57, 125.46, 124.93, 124.61, 124.50, 121.43, 108.80,
74.23, 61.85, 55.80, 29.92; HRMS: C17H17O4 found as [M+H]+:
285.1128 (Calculated for [M+H]+: 285.1127).
4.1.5.6. 6-(4,7-Dimethoxynaphthalen-1-yl)-5,6-dihydro-2H-pyran-2-
one (15). Purification of crude product by column chromatography
yielded 38 mg of 6-(4,7-dimethoxynaphthalen-1-yl)-5,6-dihydro-
2H-pyran-2-one as white solid with 97% yield. Rf: 0.22 (1:2,
EtOAc:Hexane); 1H NMR (400 MHz, CDCl3) d 8.25 (d, J = 9.2 Hz,
1H, naphthalene C5-H), 7.53 (d, J = 8.1 Hz, 1H, naphthalene C2-
H), 7.22 (d, J = 2.4 Hz, 1H, naphthalene C8-H), 7.16 (dd, J = 9.2,
2.5 Hz, 1H, naphthalene C6-H), 7.04 (ddd, J = 9.7, 6.0, 2.4 Hz, 1H,
ACOCH@CHA), 6.69 (d, J = 8.1 Hz, 1H, naphthalene C3-H), 6.23–
6.16 (m, 1H, benzylic H), 6.02 (dd, J = 11.9, 3.9 Hz, 1H,
ACOCH@CHA), 3.99 (s, 3H, AOCH3), 3.92 (s, 3H, AOCH3), 2.94–
2.82 (m, 1H, ACHHA), 2.78–2.67 (m, 1H, ACHHA); 13C NMR
(100 MHz, CDCl3) d 164.65, 158.68, 156.36, 145.54, 132.91,
125.82, 124.86, 124.64, 121.80, 121.12, 116.77, 102.54, 101.36,
77.23, 55.66, 55.50, 30.64; HRMS: C17H16O4 found as 284.1061
(Calculated: 284.0849).
4.1.5.7. 6-(6-Methoxynaphthalen-2-yl)-5,6-dihydro-2H-pyran-2-one
(16). Purification of crude product by column chromatography
yielded 332 mg of 6-(6-methoxynaphthalen-2-yl)-5,6-dihydro-
2H-pyran-2-one as white solid with 85% yield. Rf: 0.25 (1:2,
EtOAc:Hexane); 1H NMR (400 MHz, CDCl3) d 7.82–7.70 (m, 3H,
naphthalene), 7.46 (dd, J = 8.5, 1.8 Hz, 1H, naphthalene), 7.20–
7.10 (m, 2H, naphthalene), 6.98 (ddd, J = 9.8, 5.8, 2.6 Hz, 1H,
ACOCH@CHA), 6.19–6.13 (m, 1H, benzylic H), 5.58 (dd, J = 11.4,
4.5 Hz, 1H, ACOCH@CHA), 3.92 (s, 3H, AOCH3), 2.79–2.60 (m,
2H, ACH2A); 13C NMR (100 MHz, CDCl3) d 164.28, 158.30,
145.03, 134.67, 133.64, 129.71, 128.64, 127.51, 125.28, 124.32,
121.87, 119.49, 105.87, 79.55, 55.47, 31.79; HRMS: C16H14O3Na
found as [M+Na]+: 277.0849 (Calculated for [M+Na]+: 277.0841).
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4.2.1. MTT cell viability assay
To investigate the anti-proliferative activity of the compounds,
95 lL of cell suspension was inoculated into 96-well microculture
plates (GreinerBio-One) at 1x104 cells density per well in culture
media containing FBS, penicillin/streptomycin. Compounds were
dissolved in dimethyl sulfoxide (DMSO), filter sterilized, diluted
at the appropriate concentrations with the culture medium. In all
well, 1% DMSO concentration was fixed. Dilutions of compounds
were freshly prepared before each experiments. After 24 h cultiva-
tion for cell attachment, compounds were added at the final con-
centration between 50 to 0.01 lM for triplicate assay. Cells were
incubated with the compounds for 48 h and anti-proliferative
effects were determined by tetrazolium (3-(4,5-dimethylthiazol-2
-yl)-2,5-diphenyl tetrazolium bromide) based colorimetric assay.
Briefly; 4 h before the end of incubation period, medium of the
cells was removed and wells were washed by pre-warmed
phosphate-buffered saline (PBS) to remove any trace of compounds
and to prevent color interference during optical density (OD)
determination. MTT (Sigma) stock solution (5 mg/mL PBS) was
diluted at 1:10 ratio into complete culture media, 100 lL of MTT
dilution was added into each well and incubated. After 3.5 h plates
were centrifuged at 1800 rpm for 10 min at room temperatures to
avoid accidental removal of formazan crystals. Crystals were dis-
solved with 100 lL DMSO. The absorbance was determined at
540 nm. Results were represented as a percentage viability and
IC50 values are calculated by using GraphPad Prism 5 software.
4.2.2. Topo I mediated supercoiled DNA relaxation assay
Reaction mixtures were prepared according to this order: Dis-
tilled water; (needed to bring volume up to 20 lL final), 10X Assay
Buffer (350 mM Tris-HCl, (pH 8.0), 720 mM KCl, 50 mM MgCl2,
50 mM DTT, 50 mM spermidine), 0.1% bovine serum albumin,
supercoiled DNA (pHOT1, 250 ng) topoisomerase I enzyme (1U,
Topogen) and tested compounds in 2 lL DMSO.
The samples were incubated for 30 min at 37 C. 5 lL of loading
dye was added to stop the reaction. A 1% agarose gel was prepared
using 1X TAE buffer and samples were loaded after 1% agarose gel
has been solidified. (50X TAE buffer: 242 g Tris base, 57.1 mL gla-
cial acetic acid, 100 mL 0.5 M EDTA). Gel was run from 1 to
2.5 V/cm until dye front reaches the end of the gel. It was stained
with 0.5 lg/mL ethidium bromide (15 min room temperature)
and destained with distilled water for 15 min room temperature.
Gels were monitored with UV transluminator.
4.2.3. Time dependent Topo I inhibition assay
In order to determine the effects of compounds on Topo I
enzyme, Topoisomerase I Drug Screening kit (Topogen) assay was
performed. The experiment was designed to indicate time depen-
dent Topo I inhibition. In a centrifuge tube, reaction mixture was
prepared as followed; final volumes were completed to 20 lL with
dH2O, 2 lL TGS buffer (10X TGS; TGS Buffer (1X) is 10 mM Tris-HCl
pH 7.9, 1 mM EDTA, 0.15 M NaCl, 0.1% BSA, 0.1 mM Spermidine, 5%
glycerol), 2U of Topo I enzyme (Topogen) and 2 lL of 1 mM com-
pound 8 in DMSO. Then Topo I enzymes were pre-incubated with
40-methylklavuzon at 37 C for different times (0, 1, 5 and 10 min).
Afterwards, 1 lL supercoiled DNA (pHOT1 concentration of
0.25 lg/mL; 25 lg pHOT1 DNA in 100 lL TE buffer, 10 mM Tris-
HCl, pH 7.5, 1 mM EDTA) added to tubes and then tubes were incu-
bated at 37 C for 30 min. After incubation reactions were termi-
nated by adding 10% sodium dodecyl sulfate (SDS), final
concentrations of SDS were 1%, 2 lL of loading dye was added.
Samples were loaded to 1% agarose gel and run 1–2.5 V/cm until
dye reached end of gel. Gel was stained with ethidium bromide
0.5 lg/mL (EtBr) hold on shaker for 30 min and destained withdH2O for 15 min on shaker. Gels were monitored with UV
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